LISATA THERAPEUTICS INC (LSTA) Fundamental Analysis & Valuation

NASDAQ:LSTA • US1280583022

Current stock price

5.02 USD
+0.01 (+0.2%)
Last:

This LSTA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LSTA Profitability Analysis

1.1 Basic Checks

  • LSTA had negative earnings in the past year.
  • LSTA had a negative operating cash flow in the past year.
  • In the past 5 years LSTA always reported negative net income.
  • In the past 5 years LSTA always reported negative operating cash flow.
LSTA Yearly Net Income VS EBIT VS OCF VS FCFLSTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • LSTA's Return On Assets of -83.84% is on the low side compared to the rest of the industry. LSTA is outperformed by 68.67% of its industry peers.
  • The Return On Equity of LSTA (-105.00%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -83.84%
ROE -105%
ROIC N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
LSTA Yearly ROA, ROE, ROICLSTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

  • LSTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSTA Yearly Profit, Operating, Gross MarginsLSTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LSTA Health Analysis

2.1 Basic Checks

  • LSTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for LSTA has been increased compared to 1 year ago.
  • Compared to 5 years ago, LSTA has more shares outstanding
  • There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LSTA Yearly Shares OutstandingLSTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
LSTA Yearly Total Debt VS Total AssetsLSTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • LSTA has an Altman-Z score of -32.00. This is a bad value and indicates that LSTA is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -32.00, LSTA is doing worse than 89.36% of the companies in the same industry.
  • There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32
ROIC/WACCN/A
WACC9.19%
LSTA Yearly LT Debt VS Equity VS FCFLSTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • LSTA has a Current Ratio of 4.72. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 4.72, LSTA perfoms like the industry average, outperforming 53.97% of the companies in the same industry.
  • LSTA has a Quick Ratio of 4.72. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
  • LSTA has a Quick ratio (4.72) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.72
Quick Ratio 4.72
LSTA Yearly Current Assets VS Current LiabilitesLSTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. LSTA Growth Analysis

3.1 Past

  • LSTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.14%, which is quite good.
EPS 1Y (TTM)15.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • LSTA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.18% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1.19%
EPS Next 2Y26.17%
EPS Next 3Y19.8%
EPS Next 5Y12.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSTA Yearly Revenue VS EstimatesLSTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2022 2024 2027 2028 2029 2030 2031 50M 100M 150M 200M
LSTA Yearly EPS VS EstimatesLSTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. LSTA Valuation Analysis

4.1 Price/Earnings Ratio

  • LSTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LSTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSTA Price Earnings VS Forward Price EarningsLSTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSTA Per share dataLSTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LSTA's earnings are expected to grow with 19.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.17%
EPS Next 3Y19.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LSTA Dividend Analysis

5.1 Amount

  • No dividends for LSTA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LSTA Fundamentals: All Metrics, Ratios and Statistics

LISATA THERAPEUTICS INC

NASDAQ:LSTA (4/2/2026, 8:00:01 PM)

5.02

+0.01 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners8.05%
Inst Owner Change-4.74%
Ins Owners9.73%
Ins Owner Change22.8%
Market Cap45.33M
Revenue(TTM)1.07M
Net Income(TTM)-18.24M
Analysts82.22
Price Target11.56 (130.28%)
Short Float %0.21%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.38%
Min EPS beat(2)10.21%
Max EPS beat(2)18.55%
EPS beat(4)3
Avg EPS beat(4)14.02%
Min EPS beat(4)-1.74%
Max EPS beat(4)29.05%
EPS beat(8)7
Avg EPS beat(8)17.46%
EPS beat(12)11
Avg EPS beat(12)19.51%
EPS beat(16)13
Avg EPS beat(16)-30.07%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 42.37
P/FCF N/A
P/OCF N/A
P/B 2.61
P/tB 2.63
EV/EBITDA N/A
EPS(TTM)-2.13
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpS0.12
BVpS1.92
TBVpS1.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -83.84%
ROE -105%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.72
Quick Ratio 4.72
Altman-Z -32
F-Score4
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.95%
EPS Next Y1.19%
EPS Next 2Y26.17%
EPS Next 3Y19.8%
EPS Next 5Y12.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.04%
EBIT Next 3Y-10.73%
EBIT Next 5Y-1.14%
FCF growth 1Y23.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.19%
OCF growth 3YN/A
OCF growth 5YN/A

LISATA THERAPEUTICS INC / LSTA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LISATA THERAPEUTICS INC (LSTA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LSTA.


What is the valuation status for LSTA stock?

ChartMill assigns a valuation rating of 0 / 10 to LISATA THERAPEUTICS INC (LSTA). This can be considered as Overvalued.


What is the profitability of LSTA stock?

LISATA THERAPEUTICS INC (LSTA) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for LSTA stock?

The Earnings per Share (EPS) of LISATA THERAPEUTICS INC (LSTA) is expected to grow by 1.19% in the next year.